Medicinal potential of ciprofloxacin and its derivatives

Future Medicinal Chemistry

Volumn 5, Issue 1, 2013, Pages 81-96

  Castro, William ^a   Navarro, Maribel ^b   Biot, Christophe ^c  

^a INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

^b MURDOCH UNIVERSITY   (Australia)

^c UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 6 FLUORO 3 1,3,4 OXADIAZOL 2 YL 7 PIPERAZINO 1,4 DIHYDRO 4 QUINOLINONE DERIVATIVE; 1 CYCLOPROPYL 6 FLUORO 3 [5 (4 NITROPHENYL) 1,3,4 OXADIAZOL 2 YL] 7 PIPERAZINO 1,4 DIHYDRO 4 QUINOLINONE; AMINOGLYCOSIDE; ATOVAQUONE; BETA LACTAM DERIVATIVE; CARBAPENEM DERIVATIVE; CHLOROQUINE; CIPROFLOXACIN; CLINDAMYCIN; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MEFLOQUINE; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUININE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TAMOXIFEN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIMALARIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APICOPLAST; BACTERIAL INFECTION; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; INFECTION PREVENTION; MALARIA FALCIPARUM; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; HUMANS; MALARIA, FALCIPARUM; MICROBIAL SENSITIVITY TESTS; NEOPLASMS;

EID: 84871590453     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.181     Document Type: Review

References (118)

1. Hooper DC, Rubinstein E. Quinolone Antimicrobial Agents (Third edition). ASM Press, Washington, DC, USA (2003).
2. King DE, Malone R, Lilley SH. New classification and update on the quinolone antibiotics. Am. Fam. Phys. 61(9), 2741-2748 (2000).
3. Lietman PS. Fluoroquinolone toxicities: An update. Drugs. 49, 159-163 (1995).
4. Emami S, Shafiee A, Foroumadi A. Structural features of new quinolones and relationship to antibacterial activity against Gram-positive bacteria. Mini Rev. Med. Chem. 6, 375-386 (2006).
5. Hooper DC. Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect. Dis. 2, 530-538 (2002).
6. Turel I. The interactions of metal ions with quinolone antibacterial agents. Coord. Chem. Rev. 232, 27-47 (2002).
7. Scully BE, Jules K, Chin NX et al. Effect of ciprofloxacin on fecal flora of patients with cystic fibrosis and other patients treated with oral ciprofloxacin. Am. J. Med. 82, 336-338 (1987).
8. Abraham DJ. Burger's Medicinal Chemistry Drug Discovery. John Wiley and Sons, NJ, USA, 582-587 (2003).
9. Campoli-Richards DM, Monk JP, Price A et al. Ciprofloxacin. A review of its antibacterial activity, pharmacokinetics properties and therapeutics use. Drugs 35, 373-447 (1998).
10. Eliopoulos GM. In vitro activity of fluoroquinolones against Gram-positive bacteria. Drugs 49, 48-57 (1995).
11. Bazile-Pham-Khac S Truong QC, Lafont JP et al. Resistance to fluoroquinolones in Escherichia coli isolated from poultry. Antimicrob. Agents Chemother. 40(6), 1504-1507 (1996).
12. Lontie ML, Vanerdeweghe PE. Interscience conference on antimicrobial agents and chemotherapy. Presented at: 43rd annual interscience conference on antimicrobial agents and chemotherapy. Chicago, IL, USA, 14-17 September 2003.
13. Karlowsky JA, Draghi DC, Jones ME et al. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob. Agents Chemother. 47(5), 1681-1688 (2003).
14. Chambers HF. Sulfonamides, Trimethoprim, and quinolones. In: Basic and Clinical Pharmacology. Katzung BG (Ed.). Boston, MA, USA, 777-780 (2004).
15. Brown JC, Shanahan PM, Jesudason MV et al. Mutations responsible for reduced susceptibility to 4-quinolones in clinical isolates of multi-resistant Salmonella typhi in India. J. Antimicrob. Chemother. 37(5), 891-900 (1996).
16. Threlfall EJ, Skinner JA, Ward LR. Decreased in vitro susceptibility to ciprofloxacin in resistant Salmonella serotypes typhi and paratyphi A. J. Antimicrob. Chemother. 7(3), 448-450 (2001).
17. Nagai K, Davies TA, Dewasse BE. Single and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J. Antimicrob. Chemother. 48, 365-374 (2001).
18. Livermore DM, James D, Reacher M et al. Trends in Fluoroquinolone (ciprofloxacin) resistance in enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg. Inf. Dis. 8(5) 473-478 (2002).
19. Tomisic ZB, Kujundzic N, Krajacic MB et al. Molecular structures of new ciprofloxacin derivatives. J. Mol. Struc. 611, 73-81 (2002).
20. Kerns RJ, Rybak MJ, Kaatz GW et al. Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of Staphylococcus aureus. Bioorg. Med. Chem. Lett. 13, 1745-1749 (2003).
21. Gould KA, Pan X, Kerns RJ et al. Ciprofloxacin dimers target gyrase in Streptococcus pneumonia. Antimicrob. Agents Chemother. 48, 2108-2115 (2004).
22. Al-Soud YA, Al-Masoudi NA. A new class of dihaloquinolones bearing Ń-Aldehydoglycosylhydrazides, mercapto-1,2,4-triazole, oxadiazoline and a-Amino ester precursors: Synthesis and antimicrobial activity. J. Braz. Chem. Soc. 14(5), 790-796 (2003).
23. Foroumadi A, Emami SM, et al. Synthesis and antibacterial activity of N-[2-(5-bromothiophen-2-yl)-2-oxoethyl] and N-[(2-5-bromothiophen-2-yl)-2- oximinoethyl] derivatives of piperazinyl quinolones. Bioorg. Med. Chem. Lett. 15, 4536-4539 (2005).
24. Foroumadi A, Emami S, Hassanzadeh A et al Synthesis and antibacterial activity of N-(5-benzylthio-1,3,4-thiadiazol-2-yl) and N-(5-benzylsulfonyl-1,3, 4-thiadiazol-2-yl) piperazinyl quinolone derivatives. Bioorg. Med. Chem. Lett. 15, 4488-4492 (2005).
25. Foroumadi A, Oboudiat M, Emami S et al. Synthesis and antibacterial activity of N-[2-[5-(methylthio)thiophen-2-yl]-2-oxoethyl] and N-[2-[5-(methylthio)thiophen-2-yl]-2-(oxyimino)ethyl]piperazinylquinolone derivatives. Bioorg. Med. Chem. 14, 3421-3427 (2006).
26. Srivastava BK, Solanki M, Mishra B et al Synthesis and antibacterial activity of 4,5,6,7-tetrahydro-thieno[3,2-c]pyridine quinolones Bioorg. Med. Chem. Lett. 17, 1924-1929 (2007).
27. Vila J, Sanchez-Cespedes J, Sierra JM et al. Antibacterial evaluation of a collection of norfloxacin and ciprofloxacin derivatives against multiresistant bacteria. Intern. J. Antimicrob. Agents 28, 19-24 (2008).
28. German N, Wei P, Kaatz GW et al. Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pump. Eur. J. Med. Chem. 43 2453-2463 (2008).
29. Lopez-Gresa MP, Ortiz R, Perello L et al. Interactions of metal ions with two quinolone antimicrobial agents (cinoxacin and ciprofloxacin): Spectroscopic and x-ray structural characterization. Antibacterial Studies. J. Inorg. Biochem. 92, 65-74 (2002).
30. Zeiler HJ, Grohe K. The in vitro and in vivo activity of ciprofloxacin. Eur. J. Clin. Microbiol. 3(4), 339-343 (1984).
31. Chohan ZH, Supuran CT, Scozzafava A. Metal binding and antibacterial activity of ciprofloxacin complexes. J. Enz. Inh. Med. Chem. 20(3), 303-307 (2005).
32. Obaleye JA, Akinremi CA, Balogun EA et al. Toxicological studies and antimicrobial properties of some iron(III) complexes of ciprofloxacin. African J. Biotech. 6(24), 2826-2832, (2007).
33. Thakre YM, Choudhary MD. Synthesis, characterization and evaluation of derivative of ciprofloxacin (1-cyclopropyl-6-fluoro-4-oxo-7-[4-(phenyl carbonyl) piperazin-1-yl]-1, 4-dihydroquinoline-3-carboxylic acid) and their complexes. J. Chem. Pharm. Res. 3(5), 390-398 (2011).
34. Divo AA, Sartorelli AC, Patton CL et al. Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother. 32, 1182-1186 (1988).
35. Salmon D, Deloron P, Gaudin C et al. Activities of perfloxacin and ciprofloxacin against experimental malaria in mice. Antimicrob. Agents Chemother. 34, 2327-2330 (1990).
36. Hamzah J, Skinner-Adams T, Davis TM. In vitro antimalarial activity of trovafloxacin, a fourth-generation fluoroquinolone. Acta Trop. 74, 39-42 (2000).
37. Pradines B, Rogier C, Fusai T et al. In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron. Antimicrob. Agents Chemother. 45, 1746-1750 (2001).
38. Mahmoudi N, Ciceron L, Franetich JF et al. In vitro activities of 25 quinolones and fluoroquinolones against liver and blood stage Plasmodium spp. Antimicrob. Agents Chemother. 47, 2636-2639 (2003).
39. Kaur K, Jain M, Reddy RP et al. Quinolines and structurally related heterocycles as antimalarials. Eur. J. Med. Chem. 45, 3245-3264 (2010).
40. McClean KL, Hitchman D, Shafran SD. Norfloxacin is inferior to chloroquine for falciparum malaria in northwestern Zambia: A comparative clinical trial. J. Inf. Dis. 165, 904-907 (1992).
41. Stromberg A, Bjorkman A. Ciprofloxacin does not achieve radical cure of Plasmodium falciparum infection in Sierra Leone. Trans. R. Soc. Trop. Med. Hyg. 86, 373 (1992).
42. Pradines B, Rogier C, Fusai T et al. In vitro activities of antibiotics against Plasmodium falciparum are inhibited by iron. Antimicrob. Agents Chemother. 45, 1746-1750 (2001).
43. Gbotosho GO, Happi CT, Woranola O et al. Interaction between ciprofloxacin and chloroquine in miceinfected with chloroquine resistant Plasmodium berghei. Parasitol. Res. 110, 895-899 (2012).
44. Andrade AA, de Pilla Varotti F, de Freitas IO et al. Enhanced activity of mefloquine and artesunic acid against Plasmodium falciparum in vitro and P. berghei in mice by combination with ciprofloxacin. Eur. J. Pharmacol. 558(1-3), 194-198 (2007).
45. Goodman CD, Su V, McFadden GI. The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 152, 181-191 (2007).
46. Navarro M, Castro W, Biot C Bioorganometallic compounds with antimalarial targets: Inhibiting hemozoin formation. 31(16), 5715-5727 (2012).
47. Van Staveren DR, Metzler-Nolte N. Bioorganometallic Chemistry of Ferrocene. Chem. Rev. 104, 5931-5985 (2004).
48. Gasser G, Metzler-Nolte N. The potential of organometallic complexes in medicinal chemistry. Curr. Opin. Chem. Biol. 16, 84-91 (2012).
49. Gasser G, Ott I, Metzler-Nolte N. Organometallic anticancer compounds. J. Med. Chem. 54, 3-25 (2011).
50. Dubar F, Anquetin G, Pradines B et al. enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/ bioorganometallic approach. J. Med. Chem. 52, 7954-7957 (2009).
51. Chavain N, Vezin H, Dive D et al. Investigation of the redox behavior of ferroquine, a new antimalarial. Mol. Pharmaceutics 5, 710-716 (2008).
52. Biot C, Taramelli D, Forfar-Bares I et al. Insights into the mechanism of action of ferroquine. Relationship between physicochemical properties and antiplasmodial activity. Mol. Pharmaceutics. 2, 185-193 (2005).
53. Dubar F, Wintjens R, Martins-Duarte ES et al. Ester prodrugs of ciprofloxacin as DNA-gyrase inhibitors: Synthesis, antiparasitic evaluation and docking studies. Med. Chem. Commun. 2, 430-435 (2011).
54. Houston S, Fanning A. Current and potential treatment of tuberculosis. Drugs 48, 689-708 (1994).
55. Jacobs RF. Multiple-drug-resistant tuberculosis. Clin. Infect. Dis. 19(1), 1-10 (1994).
56. Alland D, Kalkut GE, Moss AR et al. Transmission of tuberculosis in New York City Y an analysis by DNA fingerprinting and conventional epidemiologic methods. N. Engl. J. Med. 330, 1710-1716 (1994).
57. Sato K, Tomioka H, Sano C et al. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines J. Antimicrob. Chemother. 52, 199-203 (2003).
58. Maxwell A. DNA gyrase as a drug target. Trends Microbiol. 5, 102-108 (1997).
59. Alangaden GJ, Lerner SA. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Infect. Dis. 25, 1213-1221 (1997).
60. Zhao YL, Chen YL, Sheu JY et al. Synthesis and antimycobacterial evaluation of certain fluoroquinolone derivatives. Bioorg. Med. Chem. 13, 3921-3926 (2005).
61. Sriram D, Yogeeswari P, Basha JS et al. Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. Bioorg. Med. Chem. 13, 5774-5778 (2005).
62. Talath S, Gadad AK. Synthesis, antibacterial and antitubercular activities of some 7-[4-(5-Amino-1,3,4 thiadiazole-2-sulfonyl)-piperazin-1-yl] fluoroquinolone derivatives. Eur. J. Med. Chem. 41, 918-924 (2006).
63. Nieto MJ, Alovero FL, Manzo RH et al. Benzenesulfonamide analogs of fluoroquinolones. Antibacterial activity and QSAR studies. Eur. J. Med. Chem. 40(4), 361-369 (2005).
64. Wang X. Inhibition of the tax-dependent human T-lymphotropic virus type I replication in persistently infected cells by the fluoroquinolone derivative K-37. Mol. Pharmacol. 61(6), 1359-1365 (2002).
65. Shammas MA, Shmookler Reis MA et al. Telomerase inhibition and cell growth arrest by Gquadruplex interactive agent in multiple myeloma. Mol. Cancer Ther. 2, 825-833 (2003).
66. Kim MY, Duan W, Gleason-Guzman M et al. Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes. J. Med. Chem. 46, 571-583 (2003).
67. Chu DTW, Hallas R, Clement JJ et al. Synthesis and antitumor activities of quinolone antiplastic agents. Drugs Exp. Clin. Res. 18, 275-282 (1992).
68. Permana PA, Snapka RM, Shen LL et al. Quinobenoxazines: A class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors. Biochemistry 33, 11333-11339 (1994).
69. Ahmeda A, Daneshtalab M. nonclassical biological activities of quinolone derivatives. J. Pharm. Pharmaceut. Sci. 15(1), 52 -72, (2012).
70. Hooper DC. Mode of Action of Fluoroquinolones. Drugs 58, 6-10 (1999).
71. Foroumadi A, Emami S, Rajabalian S et al. N-substituted piperazinyl quinolones as potential cytotoxic agents: StructureYactivity relationships study. Biomed. Pharmacother. 63, 216-220 (2009).
72. Berger JM, Gamblin SJ, Harrison SC et al Structure and mechanism of DNA topoisomerase II. Nature 379, 225-232 (1996).
73. Gootz TD, Birghty KE. In: The quinolones (2nd Edition). Andriole VT (Ed.). Academic Press, CA, USA, 29 (1998).
74. Spicer J, Finlay G, Baguley B et al. Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity. Anticancer Drug Des. 14, 37-45 (1999).
75. Chu DTW, Hallas R, Tanaka SK et al. Synthesis and antitumour activities of tetracyclic quinolone antineoplastic agents. Drugs Exp. Clin. Res. 20, 177-183 (1994).
76. Shaharyar M, Ashraf Ali EM, Abdullah MM. Synthesis and antiproliferative activity of 1-[(sub)]-6-fluoro-3-[(sub)]-1,3,4-oxadiazol-2-yl-7-piperazino-1,4- dihydro-4-quinolone derivatives. Med. Chem. Res. 16, 292-299 (2007).
77. Sriram D, Yogeeswari P, Senchani G et al. Newer tetracycline derivatives: Synthesis, anti-HIV, antimycobacterial activities and inhibition of HIV-1 integrase. Bioorg. Med. Chem. Lett. 17, 2372-2375 (2007).
78. Azéma J, Guidetti B, Dewelle J et al. 7-((4-Substituted)piperazin- 1-yl) derivatives of ciprofloxacin: Synthesis and in vitro biological evaluation as potential antitumor agents. Bioorg. Med. Chem. 17, 5396-5407 (2009).
79. Alipour E, Hosseini NM, Panah F et al. Synthesis and in vitro cytotoxic activity of N-2-(2-furyl)-2-(chlorobenzyloxyimino) ethyl ciprofloxacin derivatives. J. Chem. 8(3), 1226-1231 (2011).
80. Turel I. The interactions of metal ions with quinolone antibacterial agents. Coord. Chem. Rev. 232, 27-47 (2002).
81. Walters JD, Zhang F, Nakkula RJ. Mechanism of fluoroquinolone transport by human neutrophils. Antimicrob. Agents Chemother. 43, 2710-2715 (1999).
82. Sharma PC, Jain A, Jain S et al. Ciprofloxacin: Review on developments in synthetic, analytical, and medicinal aspects. J. Enz. Inhib. Med. Chem. 25(4), 577-589 (2010).
83. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61, 377-392 (1997).
84. Hawkey PM. Mechanisms of quinolone action and microbial response. J. Antimicrob. Chemother. 51(Suppl. 1), 29-35 (2003).
85. Gatto B, Capranico G, Palumbo M. Drugs acting on DNA topoisomerases: Recent advances and future perspectives. Curr. Pharmaceut. Design 5 195-216 (1999).
86. Hooper DC. Quinolone mode of action Y new aspects. Drugs 45, 8-14 (1993).
87. Hooper DC. Quinolone mode of action. Drugs 49 10-15 (1995).
88. Huff AC, Robinson RG, Evans AC et al. DNA sequence preferences at sites cleaved by human DNA topoisomerase II in response to novel quinolone derivatives. Anticancer Drug Res. 10(3) 251-276 (1995).
89. Shen LL, Pernet AG, Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: The target of the drugs is DNA. Proc. Natl Acad. Sci. USA 82(2), 307-311 (1985).
90. Shen LL, Mitscher LA, Sharma PN et al. Mechanism of inhibition of DNA gyrase by quinolone antibacterials: A cooperative drug-DNA binding model. Biochemistry 28 3886-3894 (1989).
91. Shen LL. A reply: 'do quinolones bind to DNA?' Y yes. Biochem. Pharmacol. 38(12), 2042-2044 (1989).
92. Son GS, Yeo JA, Kim MS et al. Binding mode of norfloxacin to calf thymus DNA. J. Am. Chem. Soc. 120, 6451-6457 (1998).
93. Son GS, Yeo JA, Kim JM et al. Base specific complex formation of norfloxacin with DNA. Biophys. Chem. 74, 225-236 (1998).
94. Crumplin GC, Smith JT. Nalidixic acid and bacterial chromosome replication. Nature 260, 643-644 (1976).
95. Palu G, Valisena S, Peracchi M et al. Do quinolones bind to DNA? Biochem. Pharmacol. 37, 1887-1888 (1988).
96. Chen CR, Malik M, Snyder M et al. DNA gyrase and topoisomerase IV on the bacterial chromosome: Quinolone-induced DNA cleavage. J. Mol. Biol. 258 627-637 (1996).
97. Robinson MJ, Martin BA, Gootz TD et al. Effects of quinolone derivatives on eukaryotic topoisomerase II. A novel mechanism for enhancement of enzyme-mediated DNA cleavage. J. Biol. Chem. 266, 14585-14592 (1991).
98. Anderson VE, Gootz TD, Osheroff N. Topoisomerase IV catalysis and the mechanism of quinolone action. J. Biol. Chem. 273, 17879-17885 (1998).
99. Kampranis SC, Maxwell A. The DNA gyrase-quinolone complex: ATP hydrolysis and the mechanism of DNA cleavage. J. Biol. Chem. 273, 22615-22626 (1998).
100. Bailly C, Colson P, Houssier C. The orientation of norfloxacin bound to double-stranded DNA. Biochem. Biophys. Res. Co. 243, 844-848 (1998).
101. Robles J, Martin-Polo J, Alvarez-Valtierra L et al. A theoretical-experimental study on the structure and activity of certain quinolones and the interaction of their Cu(II)-complexes on a DNA model. Metal Based Drugs 7(6), 301-311 (2000).
102. Sissi C, Perdona E, Domenici E et al. Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions. J. Mol. Biol. 311, 195-203 (2001).
103. Levine ND. Phylum Apicomplexa. An Illustrated Guide to the Protozoa (Lee JJ, Hunter SH, Bovee EC (Eds). Society of Protozoologists, Allen Press, Lawrence, KS, USA, 322-374 (1985).
104. McFadden GI, Reith ME, Munholland J, Lang-Unnasch N. Plastid in human parasites. Nature 381, 482 (1996).
105. Pfefferkorn ER, Borotz SE. Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin. Antimicrob. Agents Chemother. 38, 31-37 (1994).
106. Fichera ME, Bhopale MK, Roos DS. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob. Agents Chemother. 39, 1530-1537 (1995).
107. Gardner MJ, Feagin JE, Moore DJ et al. Organisation and expression of small subunit ribosomal RNA genes encoded by a 35-kilobase circular DNA in Plasmodium falciparum. Mol. Biochem. Parasitol. 48, 77-88 (1991).
108. Wilson RJM, Denny PW, Preiser PR et al. Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum. J. Mol. Biol. 261, 155-172 (1996).
109. Feagin JE. The 6-kb element of Plasmodium falciparum encodes mitochondrial cytochrome genes. Mol. Biochem. Parasitol. 52, 145-148 (1992).
110. Vaidya AB, Akella R, Suplick K. Sequences similar to genes for two mitochondrial proteins and portions of ribosomal RNA in tandemly arrayed 6-kilobase-pair DNA of a malarial parasite. Mol. Biochem. Parasitol. 35, 97-107 (1989).
111. Wilson RJ, Williamson DH. Extrachromosomal DNA in the Apicomplexa. Microbiol. Mol. Biol. Rev. 61(1), 1-16 (1997).
112. Köhler S, Delwiche CF, Denny PW et al. A plastid of probable green algal origin in apicomplexan parasites. Science 275, 1485-1489 (1997).
113. McFadden GI, van Dooren GG. Evolution: Red algal genome affirms a common origin of all plastids. Curr. Biol. 14, R514YR516 (2004).
114. Kohler S, Delwiche CF, Denny PW et al. A plastid of probable green algal origin in apicomplexan parasites. Science, 275, 1485-1489 (1997).
115. Pfefferkorn ER, Nothnagel RF, Borotz SE. Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant. Antimicrob. Agents Chemother. 36, 1091-1096 (1992).
116. Fichera ME, Bhopale MK, Roos DS. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob. Agents Chemother. 39, 1530-1537 (1995).
117. Beckers CJ, Roos DS, Donald RG et al. Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii: Implications for the target of macrolide antibiotics. J. Clin. Invest. 95, 367-376 (1995).
118. Fichera ME, Roos DS, A plastid organelle as a drug target in apicomplexan parasites. Nature 390, 407-409 (1997).